The European Medicines Evaluation AgencyBMJ 1994; 308 doi: https://doi.org/10.1136/bmj.308.6926.430 (Published 12 February 1994) Cite this as: BMJ 1994;308:430
- N Bosanquet
The new agency can be an important catalyst for drug innovation in Europe The European Medicines Evaluation Agency (EMEA) is to be set up in London - a decision that has been wanted and welcomed by the pharmaceutical industry. Many companies are tired of the long delays and the extra work required in submitting applications to 12 or more different regulatory agencies in the separate states of the European Union. As the life cycle of new drugs becomes steadily shorter, long delays - a year or more has been common in Germany - have become burdensome. A single registration procedure could lead to new products being introduced simultaneously in the 12 different European markets.1,2
The agency will have a twin track procedure: one for centralised community licensing of biotech …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial